Intervention Review

Angiogenesis inhibitors for the treatment of ovarian cancer

  1. Kezia Gaitskell1,
  2. Igor Martinek2,
  3. Andrew Bryant3,
  4. Sean Kehoe2,
  5. Shibani Nicum4,
  6. Jo Morrison5,*

Editorial Group: Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group

Published Online: 7 SEP 2011

Assessed as up-to-date: 20 JUL 2011

DOI: 10.1002/14651858.CD007930.pub2


How to Cite

Gaitskell K, Martinek I, Bryant A, Kehoe S, Nicum S, Morrison J. Angiogenesis inhibitors for the treatment of ovarian cancer. Cochrane Database of Systematic Reviews 2011, Issue 9. Art. No.: CD007930. DOI: 10.1002/14651858.CD007930.pub2.

Author Information

  1. 1

    London School of Hygiene & Tropical Medicine, London, UK

  2. 2

    Oxford Cancer and Haematology Centre, Oxford Gynaecological Oncology Centre, Level 0, Oxford, UK

  3. 3

    Newcastle University, Institute of Health and Society, Newcastle upon Tyne, UK

  4. 4

    Oxford Cancer and Haematology Centre, NHS Department of Oncology, Level 2, Oxford, UK

  5. 5

    Musgrove Park Hospital, Department of Obstetrics and Gynaecology, Taunton, Somerset, UK

*Jo Morrison, Department of Obstetrics and Gynaecology, Musgrove Park Hospital, Taunton, Somerset, TA1 5DA, UK. jo.morrison@obs-gyn.ox.ac.uk.

Publication History

  1. Publication Status: New
  2. Published Online: 7 SEP 2011

SEARCH

  1. Current Version

    Angiogenesis inhibitors for the treatment of ovarian cancer

    Kezia Gaitskell, Igor Martinek, Andrew Bryant, Sean Kehoe, Shibani Nicum and Jo Morrison

    Version of Record online: 7 SEP 2011 | DOI: 10.1002/14651858.CD007930.pub2

Previous versions of this article and their online publication dates

  1. Version 1

    Angiogenesis-inhibitors for the treatment of ovarian cancer

    Kezia Gaitskell, Igor Martinek, Shibani Nicum, Sean Kehoe and Jo Morrison

    Version of Record online: 8 JUL 2009 | DOI: 10.1002/14651858.CD007930